Previous Article | Next Article ![]()
J. Virol., 04 1995, 2004-2015, Vol 69, No. 4
Y Yang, Q Li, HC Ertl and JM Wilson
Recombinant adenoviruses are an attractive vehicle for gene therapy to the
lung in the treatment of cystic fibrosis (CF). First-generation viruses
deleted of E1a and E1b transduce genes into airway epithelial cells in
vivo; however, expression of the transgene is transient and associated with
substantial inflammatory responses, and gene transfer is significantly
reduced following a second administration of the virus. In this study, we
have used mice deficient in immunological effector functions in combination
with adoptive and passive transfer techniques to define antigen-specific
cellular and humoral immune responses that underlie these important
limitations. Our studies indicate that major histocompatibility complex
class I-restricted CD8+ cytotoxic T lymphocytes are activated in response
to newly synthesized antigens, leading to destruction of virus infected
cells and loss of transgene expression. Major histocompatibility complex
class II- associated presentation of exogenous viral antigens activates
CD4+ T- helper (TH) cells of the TH1 subset and, to a lesser extent, of the
TH2 subset. CD4+ cell-mediated responses are insufficient in the absence of
cytotoxic T cells to completely eliminate transgene containing cells;
however, they contribute to the formation of neutralizing antibodies in the
airway which block subsequent adenovirus-mediated gene transfer. Definition
of immunological barriers to gene therapy of cystic fibrosis should
facilitate the design of rational strategies to overcome them.
Copyright © 1995, American Society for Microbiology
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
Institute for Human Gene Therapy, University of Pennsylvania Medical Center, Philadelphia 19104.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|